PL2205720T3 - Kompozycja do leczenia stwardnienia rozsianego - Google Patents

Kompozycja do leczenia stwardnienia rozsianego

Info

Publication number: PL2205720T3
Authority: PL; Poland
Prior art keywords: treatment; composition; multiple sclerosis; sclerosis
Prior art date: 2007-10-17

Application number

PL08838676T

Other languages

English (en)

Inventor

Arnaud Foussat

Original Assignee

Txcell

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-17

Filing date

2008-10-17

Publication date

2017-06-30

2007-10-17 Priority claimed from US11/873,623 external-priority patent/US20090104142A1/en

2008-10-17 Application filed by Txcell filed Critical Txcell

2017-06-30 Publication of PL2205720T3 publication Critical patent/PL2205720T3/pl

Links

201000006417 multiple sclerosis Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Cell Biology (AREA)
Mycology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Rheumatology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL08838676T 2007-10-17 2008-10-17 Kompozycja do leczenia stwardnienia rozsianego PL2205720T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US11/873,623 US20090104142A1 (en)	2007-10-17	2007-10-17	Compositions for treating multiple sclerosis
EP07301475A EP2050814A1 (en)	2007-10-17	2007-10-17	Compositions for treating multiple sclerosis
EP08838676.8A EP2205720B1 (en)	2007-10-17	2008-10-17	Compositions for treating multiple sclerosis

Publications (1)

Publication Number	Publication Date
PL2205720T3 true PL2205720T3 (pl)	2017-06-30

Family

ID=40089903

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL08838676T PL2205720T3 (pl)	2007-10-17	2008-10-17	Kompozycja do leczenia stwardnienia rozsianego

Country Status (18)

Country	Link
US (2)	US9517253B2 (pl)
EP (2)	EP2050814A1 (pl)
JP (2)	JP2011500645A (pl)
KR (1)	KR20100074286A (pl)
CN (1)	CN101842478B (pl)
AU (1)	AU2008313694B2 (pl)
CA (1)	CA2702634C (pl)
CY (1)	CY1118710T1 (pl)
DK (1)	DK2205720T3 (pl)
ES (1)	ES2618583T3 (pl)
HR (1)	HRP20170353T1 (pl)
HU (1)	HUE032066T2 (pl)
LT (1)	LT2205720T (pl)
PL (1)	PL2205720T3 (pl)
PT (1)	PT2205720T (pl)
RU (1)	RU2492234C2 (pl)
SI (1)	SI2205720T1 (pl)
WO (1)	WO2009050283A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010132697A2 (en) *	2009-05-13	2010-11-18	Genzyme Corporation	Methods and compositions for treatment
EP2378287A1 (en) *	2010-04-15	2011-10-19	TXCell	New method for isolating Tr1 cells
EP2412802A1 (en) *	2010-07-29	2012-02-01	TXCell	IL-13 producing TR1-like cells and use thereof
US20140348808A1 (en) *	2011-05-19	2014-11-27	Olga De La Rosa	Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
GB201300684D0 (en)	2013-01-15	2013-02-27	Apitope Int Nv	Peptide
GB201418433D0 (en) *	2014-10-17	2014-12-03	Imcyse Sa	Novel immunogenic peptides
US11236159B2 (en) *	2015-08-03	2022-02-01	Novartis Ag	Methods of treating FGF21-associated disorders
RU2600160C1 (ru) *	2015-08-07	2016-10-20	Юрий Леонидович Шевченко	Способ лечения рассеянного склероза и других системных аутоиммунных заболеваний
CN105254765A (zh) *	2015-10-10	2016-01-20	江汉大学	重组蛋白MOG35-55-I-Abβ1-α1及其基因和应用
WO2018078112A1 (en) *	2016-10-27	2018-05-03	Aarhus Universitet	Glp-1 agonist (eg liraglutide) for use in the treatment of multiple sclerosis
WO2018159787A1 (ja)	2017-03-01	2018-09-07	国立大学法人北海道大学	疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法
WO2018188730A1 (en)	2017-04-11	2018-10-18	Biontech Rna Pharmaceuticals Gmbh	Rna for treatment of autoimmune diseases
JP7436383B2 (ja)	2018-04-18	2024-02-21	ユーシーエルビジネスリミテッド	操作された調節性ｔ細胞

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4008A (en) *		1845-04-22		Improvement w the manufacture of oil from resin
ES2144418T3 (es)	1991-05-31	2000-06-16	Connetics Corp	Peptidos de receptores de celulas t como agentes terapeuticos para enfermedades relacionadas con el sistema inmunitario.
US5874531A (en) *	1995-03-07	1999-02-23	President And Fellows Of Harvard College	Identification of self and non-self antigens implicated autoimmune disease
US6515016B2 (en) *	1996-12-02	2003-02-04	Angiotech Pharmaceuticals, Inc.	Composition and methods of paclitaxel for treating psoriasis
US6746670B2 (en)	2000-08-15	2004-06-08	Schering Corporation	Regulatory T cells; methods
US6670146B2 (en)	2000-10-04	2003-12-30	Schering Corporation	Regulatory T cells; methods
CA2445640A1 (en)	2001-03-23	2002-10-03	John Matsoukas	Peptide analogues of myelin basic protein epitopes in the treatment of experimental autoimmune encephalomyelitis (eae) and multiple sclerosis (ms)
FR2824567B1 (fr)	2001-05-11	2003-08-08	Inst Nat Sante Rech Med	Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
US20060057110A1 (en)	2002-06-14	2006-03-16	Yeda Research And Development Co. Ltd.	Antigen-presenting cells for neuroprotection and nerve regeneration
FR2856700B1 (fr)	2003-06-24	2007-06-08	Txcell	Procede d'identification de lymphocytes tr1 regulateurs par la presence et la surexpression de molecules specifiques et ses applications
US20080107664A1 (en) *	2003-10-17	2008-05-08	Zang Ying C Q	Method For Increasing Cd8+ Cytotoxic T Cell Responses And For Treating Multiple Sclerosis
AU2005302425A1 (en) *	2004-10-29	2006-05-11	Benaroya Research Institute At Virginia Mason	Methods of generating antigen-specific CD4+CD25+ regulatory T cells, compositions and methods of use
EP1712615A1 (en)	2005-04-15	2006-10-18	Txcell	In vitro production of a cell population using feeder cells
PT1739166E (pt)	2005-07-01	2011-09-22	Inst Nat Sante Rech Med	Obtenção de células tr1 específicas para um auto-antigénio ou antigénio de alimentos a partir de uma população de pbmc ou de leucócito

2007
- 2007-10-17 EP EP07301475A patent/EP2050814A1/en not_active Withdrawn
2008
- 2008-10-17 HU HUE08838676A patent/HUE032066T2/en unknown
- 2008-10-17 AU AU2008313694A patent/AU2008313694B2/en not_active Ceased
- 2008-10-17 PT PT88386768T patent/PT2205720T/pt unknown
- 2008-10-17 CA CA2702634A patent/CA2702634C/en not_active Expired - Fee Related
- 2008-10-17 WO PCT/EP2008/064066 patent/WO2009050283A1/en not_active Ceased
- 2008-10-17 ES ES08838676.8T patent/ES2618583T3/es active Active
- 2008-10-17 EP EP08838676.8A patent/EP2205720B1/en not_active Not-in-force
- 2008-10-17 JP JP2010529404A patent/JP2011500645A/ja active Pending
- 2008-10-17 KR KR1020107010788A patent/KR20100074286A/ko not_active Withdrawn
- 2008-10-17 SI SI200831773A patent/SI2205720T1/sl unknown
- 2008-10-17 RU RU2010119505/10A patent/RU2492234C2/ru not_active IP Right Cessation
- 2008-10-17 PL PL08838676T patent/PL2205720T3/pl unknown
- 2008-10-17 LT LTEP08838676.8T patent/LT2205720T/lt unknown
- 2008-10-17 US US12/738,706 patent/US9517253B2/en not_active Expired - Fee Related
- 2008-10-17 DK DK08838676.8T patent/DK2205720T3/en active
- 2008-10-17 CN CN200880113494.7A patent/CN101842478B/zh not_active Expired - Fee Related
- 2008-10-17 HR HRP20170353TT patent/HRP20170353T1/hr unknown
2014
- 2014-07-25 JP JP2014151551A patent/JP2014221819A/ja active Pending
2016
- 2016-10-28 US US15/336,832 patent/US20170042992A1/en not_active Abandoned
2017
- 2017-03-09 CY CY20171100305T patent/CY1118710T1/el unknown

Also Published As

Publication number	Publication date
CY1118710T1 (el)	2017-07-12
CN101842478A (zh)	2010-09-22
EP2205720B1 (en)	2016-12-14
CN101842478B (zh)	2014-04-02
EP2050814A1 (en)	2009-04-22
WO2009050283A1 (en)	2009-04-23
PT2205720T (pt)	2017-03-13
AU2008313694B2 (en)	2015-03-26
KR20100074286A (ko)	2010-07-01
HRP20170353T1 (hr)	2017-05-05
LT2205720T (lt)	2017-03-27
JP2014221819A (ja)	2014-11-27
CA2702634C (en)	2017-06-13
RU2010119505A (ru)	2011-11-27
US9517253B2 (en)	2016-12-13
AU2008313694A1 (en)	2009-04-23
ES2618583T3 (es)	2017-06-21
EP2205720A1 (en)	2010-07-14
HUE032066T2 (en)	2017-09-28
DK2205720T3 (en)	2017-03-20
SI2205720T1 (sl)	2017-04-26
RU2492234C2 (ru)	2013-09-10
JP2011500645A (ja)	2011-01-06
US20170042992A1 (en)	2017-02-16
US20100221219A1 (en)	2010-09-02
CA2702634A1 (en)	2009-04-23

Publication	Publication Date	Title
CY2023002I1 (el)	2023-06-09	Συνθεσεις και χρησεις για αντιμετωπιση πολλαπλης σκληρυνσης
PL3354276T3 (pl)	2020-09-21	Kompozycje do leczenia zapalenia przewodu pokarmowego
PL2205720T3 (pl)	2017-06-30	Kompozycja do leczenia stwardnienia rozsianego
LTPA2018014I1 (lt)	2018-12-10	Farmacinė kompozicija 514
SMAP200900085A (it)	2010-01-19	3-imidazolil-indoli per il trattamento di malattieproliferative
LT2478907T (lt)	2021-06-25	Kompozicijos vėžiui gydyti
DK2504005T3 (da)	2014-01-13	Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
PL2338519T3 (pl)	2016-06-30	Środek do leczenia zwłóknienia szpiku
HUE051206T2 (hu)	2021-03-01	Módszerek progresszív szklerózis multiplex kezelésére
DK2474321T3 (da)	2019-06-03	Sammensætninger til behandling af collagenmedierede sygdomme
PL2205273T3 (pl)	2017-09-29	Zastosowanie zmodyfikowanych komórek w leczeniu stwardnienia rozsianego
BRPI0913806A2 (pt)	2015-10-20	"composição"
BRPI0813775A2 (pt)	2015-01-06	Composição
ATE528048T1 (de)	2011-10-15	Schweisshemmende/desodorierende zusammensetzung
BRPI0911612A2 (pt)	2015-12-15	composições e métodos para o tratamento da esclerose múltipla.
BRPI0810557A2 (pt)	2016-07-19	composição
DK3300729T3 (da)	2020-01-20	Terapeutiske sammensætninger indeholdende macitentan
BRPI0811274A2 (pt)	2014-10-07	Composição
SMT201400165B (it)	2015-01-15	Composizioni e metodi per il trattamento di sclerosi multipla
BRPI0821249A2 (pt)	2015-06-16	Composição de endurecimento
PT2182988E (pt)	2014-05-16	Composição radiofarmacêutica
IL209360A (en)	2015-10-29	Medications containing pm00104 for the treatment of multiple myeloma
DK2117565T3 (da)	2012-11-19	Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
BRPI0811002A2 (pt)	2015-01-27	Composição biofertilizante
BRPI0820960A2 (pt)	2017-05-09	composição